Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
2.4
Journals
Medicina
Special Issues
New Advances in Urology and Nephrology Disease: From Diagnosis to...
share announcement

New Advances in Urology and Nephrology Disease: From Diagnosis to Treatment—2nd Edition

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Urology & Nephrology".

Deadline for manuscript submissions: 31 August 2025 | Viewed by 2625

Special Issue Editors

Dr. Razvan-Ionut Popescu

E-Mail Website
Guest Editor
Department of Urology, “Prof. Dr. Th. Burghele” Clinical Hospital, 061344 Bucharest, Romania
Interests: kidney stone; prostate cancer; renal cancer; bladder cancer; chronic kidney disease; urinary tract infections; laparoscopy and endourology
Special Issues, Collections and Topics in MDPI journals
Dr. Rǎzvan Cosmin Petca

E-Mail Website
Guest Editor
1. Department of Urology, “Carol Davila” University of Medicine and Pharmacy, 8 Eroii Sanitari Boulevard, 050474 Bucharest, Romania
2. Department of Urology, “Prof. Dr. Th. Burghele” Clinical Hospital, 20 Panduri Street, 061344 Bucharest, Romania
Interests: prostate cancer; bladder cancer; renal stone disease; kidney cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is my pleasure to invite you to contribute to this Special Issue entitled “New Advances in Urology and Nephrology Disease: From Diagnosis to Treatment—2nd Edition”. This is our new volume; we previously published 13 papers in the first volume. For more details, please visit the following link: https://www.mdpi.com/journal/medicina/special_issues/H5UI5X4Z8F.

The modern era has brought about both technological and molecular advancements in the field of medicine. Regarding the diagnosis, treatment, and progression of a variety of diseases, new frontiers and horizons have emerged over time. All of these occurrences have occurred very rapidly, and medical personnel are frequently confronted with the challenge of rapidly acquiring new information for the patient's benefit.

Urology and nephrology are two closely related specialties in which collaboration is frequently the key to effective treatment. In the disciplines of surgery and medicine, the rate of new discoveries is likely at its peak. By enhancing medical equipment robotics, laparoscopy, and endourology, as well as further training personnel, these factors can contribute to improved postoperative outcomes. Increasingly, new imaging technologies shorten the duration of the diagnostic process and enhance patients' prognoses. In the battle against chronic diseases, the emergence of new biomarkers and diagnostic schemes, as well as new treatment modalities, help urological and nephrological patients, improving their chances of recovery or their quality of life.

Modern technologies such as artificial intelligence, human augmentation, and brain science will enable greater advancements and will demonstrate their efficacy in assisting physicians in providing better medical care.

This Special Issue solicits studies that will expand the teaching and clinical application of these recent advances or their results in the fields of urology and nephrology. In addition to research that has steadily improved existing problems, we embrace papers that present new opportunities.

We cordially invite you to submit a paper to this Special Issue, and we would greatly appreciate it if you would recommend it to your colleagues. If you are interested in contributing an article, please let us know as soon as possible.

Please provide a working title and brief abstract in advance so that we can conduct a suitability check. The final submission deadline is 31 August 2025.

Dr. Razvan-Ionut Popescu
Dr. Rǎzvan Cosmin Petca
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • bladder cancer
  • renal cancer
  • kidney stones
  • urinary tract infections
  • chronic kidney disease
  • dialysis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

10 pages, 265 KiB  
Article
The Management of Ischemic Priapism Due to Sickle Cell Disease and Other Etiologies: Treatment Strategies and Indications for Penile Prosthesis Implantation in an Endemic Region
by Eser Ördek, Sadık Görür, Fatih Gökalp, Duran Kuru and Ferhat Uçurmak
Medicina 2025, 61(4), 658; https://doi.org/10.3390/medicina61040658 - 3 Apr 2025
Viewed by 403
Abstract
Background and Objectives: Priapism is a condition characterized by a prolonged erection lasting over four hours, either independent of or following sexual stimulation. The primary treatment goal for ischemic and non-ischemic priapism is timely and appropriate intervention in order to preserve erectile [...] Read more.
Background and Objectives: Priapism is a condition characterized by a prolonged erection lasting over four hours, either independent of or following sexual stimulation. The primary treatment goal for ischemic and non-ischemic priapism is timely and appropriate intervention in order to preserve erectile function and penile length. This study aims to evaluate the management of recurrent ischemic priapism in sickle cell disease (SCD) patients in an endemic region and compare it with ischemic priapism of other etiologies. Materials and Methods: Patients admitted to our hospital with a diagnosis of priapism between January 2010 and June 2024 were retrospectively reviewed. The patients were divided into two groups: ischemic priapism due to SCD and ischemic priapism due to other etiologies. Patient characteristics, treatment management, and the need for penile prosthesis (PP) were compared. Results: A total of 40 ischemic priapism patients were included in the study; 20 of them had SCD and the other 20 had priapism cases due to different etiologies. In the SCD priapism group, the rate of comorbidity and previous history of priapism were significantly (p < 0.05) higher than in the other etiologies of priapism group. Similarly, in the SCD priapism group, the hospital admission time and the rate of fibrosis findings in MRI (magnetic resonance imaging) were significantly (p < 0.05) higher than in the other priapism groups. The PP implantation rate in the SCD priapism group was found to be significantly (p < 0.05) higher than in the other priapism group. Conclusions: This study highlights the importance of early intervention and patient awareness in SCD-related ischemic priapism, recommending educational programs to improve symptom recognition and prevent complications. Full article
(This article belongs to the Special Issue New Advances in Urology and Nephrology Disease: From Diagnosis to Treatment—2nd Edition)
12 pages, 1037 KiB  
Article
The Role of microRNA in Overactive Bladder: Relationship and Clinical Correlation
by Kürşat Küçüker, Hülya Aybek, Hakan Akça, Ege Rıza Karagür, Elif Fırat, Yusuf Özlülerden, Sinan Çelen and Zafer Aybek
Medicina 2025, 61(3), 475; https://doi.org/10.3390/medicina61030475 - 8 Mar 2025
Viewed by 724
Abstract
Background and Objectives: This study aimed to determine the relationship between miRNAs and overactive bladder (OAB). We also aimed to reveal the diagnostic properties of miRNAs and their potential to predict responses to therapy. Materials and Methods: The study included 60 patients [...] Read more.
Background and Objectives: This study aimed to determine the relationship between miRNAs and overactive bladder (OAB). We also aimed to reveal the diagnostic properties of miRNAs and their potential to predict responses to therapy. Materials and Methods: The study included 60 patients with OAB as the treatment group and 60 healthy individuals as the control group. The blood levels of 15 miRNAs in both groups were determined using PCR. Also, miRNAs with high diagnostic values were identified with receiver operating characteristic (ROC) curves. Finally, the Turkish-validated OAB questionnaire form was filled out before and after the treatment by the participants in the treatment group. In this way, the relationship between OAB score changes and miRNA levels was examined. Results: The let-7a, let-7c, let-7e, let-7f, and let-7g miRNA molecules in the treatment group were higher, with a high level of significance (p = 0.0001). Additionally, the miR-135b, miR-300, miR-372, miR-373, miR-381, miR-520a, miR-520d, and miR-520e miRNA molecules were found to be statistically higher in the control group (p = 0.0001). In addition, let-7c (area under curve [AUC] = 0.985) and the let-7c + miR-381 combination (area under curve [AUC] = 1) were the highest values in the ROC analysis. Finally, after treatment in the patient group, a significant difference was detected in both miRNAs (let-7f and miR-135b) in patients with clinical improvements of 50% and above in the OAB score. Conclusions: miRNAs may help elucidate the pathophysiology of OAB. They may shed light on diagnosis and evaluation of treatment effectiveness. Full article
(This article belongs to the Special Issue New Advances in Urology and Nephrology Disease: From Diagnosis to Treatment—2nd Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

10 pages, 290 KiB  
Review
SGLT2 Inhibitors in Patients with Urogenital Malformations and Urinary Diversions: Risks, Benefits, and Clinical Considerations
by Mohammed Abdulrasak, Ali Someili and Mostafa Mohrag
Medicina 2025, 61(5), 921; https://doi.org/10.3390/medicina61050921 - 20 May 2025
Viewed by 313
Abstract
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are increasingly used in patients with type 2 diabetes, chronic kidney disease, and heart failure. However, their safety and efficacy in patients with congenital or surgically altered urogenital anatomy remains underexplored. Methods: We conducted a narrative [...] Read more.
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are increasingly used in patients with type 2 diabetes, chronic kidney disease, and heart failure. However, their safety and efficacy in patients with congenital or surgically altered urogenital anatomy remains underexplored. Methods: We conducted a narrative review of current evidence regarding the use of SGLT2i in patients with urinary tract malformations, urinary diversions, and functional voiding disorders. Key risks, clinical considerations, and management strategies were synthesized from the existing literature and case reports. Results: Patients with benign prostatic hyperplasia, vesicoureteral reflux, neurogenic bladder, nephrostomies, and ileal conduits may face increased risks of urinary tract infections, fungal colonization, and therapy-related complications due to persistent glycosuria and altered urinary flow. Nevertheless, these patients may still benefit from SGLT2i’s systemic renal and cardiovascular effects. Individualized risk assessment, close monitoring, and multidisciplinary management are essential. Conclusions: Patients with urological abnormalities represent a high-risk but potentially high-reward population for SGLT2i therapy. A cautious, tailored approach is necessary, and future dedicated research is urgently needed to better guide clinical practice. Full article
(This article belongs to the Special Issue New Advances in Urology and Nephrology Disease: From Diagnosis to Treatment—2nd Edition)

Other

Jump to: Research, Review

18 pages, 1890 KiB  
Systematic Review
Diagnostic Performance and Interobserver Agreement of the Vesical Imaging–Reporting and Data System (VI-RADS) in Bladder Cancer Staging: A Systematic Review
by Alexandru Nesiu, Dorin Novacescu, Silviu Latcu, Razvan Bardan, Alin Cumpanas, Flavia Zara, Victor Buciu, Radu Caprariu, Talida Georgiana Cut and Ademir Horia Stana
Medicina 2025, 61(3), 469; https://doi.org/10.3390/medicina61030469 - 7 Mar 2025
Viewed by 749
Abstract
Background and Objectives: The Vesical Imaging–Reporting and Data System (VI-RADS) represents a standardized approach for interpreting multiparametric magnetic resonance imaging (mp-MRI) in bladder cancer (BC) evaluation. This systematic review aimed to assess the VI-RADS’ diagnostic performance and interobserver agreement in distinguishing muscle-invasive [...] Read more.
Background and Objectives: The Vesical Imaging–Reporting and Data System (VI-RADS) represents a standardized approach for interpreting multiparametric magnetic resonance imaging (mp-MRI) in bladder cancer (BC) evaluation. This systematic review aimed to assess the VI-RADS’ diagnostic performance and interobserver agreement in distinguishing muscle-invasive from non-muscle-invasive BC, a crucial differentiation for treatment planning. Materials and Methods: A systematic literature search was conducted through PubMed, Google Scholar, and Web of Science, over an initial five-year time span, from VI-RADS’ inception (May 2018) to November 2023. Studies reporting VI-RADS’ diagnostic performance with histopathological confirmation and interobserver agreement data were included. The diagnostic accuracy was assessed using sensitivity and specificity, while interobserver agreement was evaluated using Cohen’s κ coefficient. Results: Nine studies comprising 1249 participants met the inclusion criteria. Using a VI-RADS score cutoff of ≥3, the pooled sensitivity and specificity for detecting muscle invasion were 88.2% and 80.6%, respectively. Interobserver agreement showed excellent consistency with a mean κ value of 0.82. Individual study sensitivities ranged from 74.1% to 94.6%, while specificities varied from 43.9% to 96.5%. Conclusions: VI-RADS demonstrates high diagnostic accuracy and excellent interobserver agreement in BC staging, supporting its role as a reliable non-invasive diagnostic tool. However, it should be used as a complementary tool to, not a replacement for, histopathological confirmation. Moreover, the variability in specificity suggests the need for standardized training and interpretation protocols. Clinical correlation and adequate reader experience are essential for optimal implementation. Future integration with pathological data may further enhance its predictive value. Full article
(This article belongs to the Special Issue New Advances in Urology and Nephrology Disease: From Diagnosis to Treatment—2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop